Merz Aesthetics announced the expansion of its premium BELOTERO hyaluronic acid (HA) portfolio in the United States, with FDA approval of BELOTERO VOLUME(+) to improve volume deficit in the mid-face or to correct midface contour deficiencies in adults 22 years or older, and BELOTERO INTENSE (+) to temporarily add volume and improve lip fullness in adults over the age of 215,6 the company announced in a September 14, 2026 press release.
Backed by more than two decades of international clinical experience, the portfolio now spans three complementary biomimetic HA treatments, BELOTERO BALANCE®(+), BELOTERO VOLUME®(+) and BELOTERO INTENSE®(+), designed to address a wider spectrum of provider and patient needs across facial balancing, volume restoration, contouring, and lip enhancement – all rooted in a unified philosophy of seamless tissue integration and natural-looking results.
Related: Merz Aesthetics Reinvents Belotero Syringe for Ergonomic Precision After 20 Years
Powered by Merz Aesthetics’ patented Cohesive Polydensified Matrix (CPM) gel, BELOTERO's biomimetic design enables the gel to mimic skin tissue at every depth, delivering the natural-looking results patients seek.2,9
"The FDA approvals of BELOTERO VOLUME(+) and BELOTERO INTENSE(+) represent an important milestone for Merz Aesthetics in the U.S.,” said Patrick Urban, President of Merz Aesthetics North America. "By expanding the BELOTERO portfolio and complementing our broader injectable offerings, we're strengthening our ability to support healthcare professionals with a more comprehensive range of solutions, helping them meet diverse patient needs through a single trusted partner."
For medspa owners and aesthetic providers, the approvals give practices two new HA options to consider across high-demand treatment areas. This is especially useful as the U.S. continues to see strong demand for personalized, natural-looking aesthetic outcomes, with lips and cheeks consistently ranking among the most requested treatment areas, and 74% of patients reporting a preference for treatments that enhance, rather than transform.7,8
For complete prescribing information, indications, and safety data, visit www.BELOTERO.com.
References
1. Patent Note: WO 2005/085329 “Biocompatible crosslinked gel.”
2. Casabona G., Davidovic, K., & Borrelli, M. R. 2026. Dermatologic surgery. Tissue-Plane Adaptability in Hyaluronic Acid Gels of Five Crosslinking Technologies: A Comparative Ex Vivo Ultrasound Analysis.
3. Fagien S, et al. 2019. Plast Reconstr Surg. Rheologic and Physicochemical Properties Used to Differentiate Injectable Hyaluronic Acid Filler Products.
4. Micheels P et al. 2015. J Clin Aesthet Dermatol. Treatment of Age-related Mid-face Atrophy by Injection of Cohesive Polydensified Matrix Hyaluronic Acid Volumizer.
5. Belotero Volume (+) [Prescribing Information and Instructions for Use]. IN00241-00. Merz North America, Inc; 2026.
6. Belotero Intense (+) [Prescribing Information and Instructions for Use]. IN00262-00. Merz North America, Inc; 2026.
7. Merz Aesthetics Data on File.
8. Nielsen Consumer A+U Study Data 2025
